List of Neuren Pharmaceuticals patents

Patents where

Current Assignee

Name

‌

Neuren Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7563862 Neural regeneration peptides and methods for their use in treatment of brain damage	Patent 7563862 was granted and assigned to Neuren Pharmaceuticals on July, 2009 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7563862	July 21, 2009
‌ US Patent 9212204 Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid	Patent 9212204 was granted and assigned to Neuren Pharmaceuticals on December, 2015 by the United States Patent and Trademark Office.	‌ Neuren Pharmaceuticals	‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	9212204	December 15, 2015
‌ US Patent 9708366 Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate	Patent 9708366 was granted and assigned to Neuren Pharmaceuticals on July, 2017 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	9708366	July 18, 2017
‌ US Patent 7887839 Oral formulations of glycyl-2-methylprolyl-glutamate	Patent 7887839 was granted and assigned to Neuren Pharmaceuticals on February, 2011 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7887839	February 15, 2011
‌ US Patent 7863304 Analogs of glycyl-prolyl-glutamate	Patent 7863304 was granted and assigned to Neuren Pharmaceuticals on January, 2011 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7863304	January 4, 2011
‌ US Patent 8637567 Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid	Patent 8637567 was granted and assigned to Neuren Pharmaceuticals on January, 2014 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	8637567	January 28, 2014
‌ US Patent 7714020 Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate	Patent 7714020 was granted and assigned to Neuren Pharmaceuticals on May, 2010 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7714020	May 11, 2010
‌ US Patent 7605177 Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration	Patent 7605177 was granted and assigned to Neuren Pharmaceuticals on October, 2009 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7605177	October 20, 2009
‌ US Patent 7485630 Neuroprotective macrocyclic compounds and methods for their use	Patent 7485630 was granted and assigned to Neuren Pharmaceuticals on February, 2009 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7485630	February 3, 2009
‌ US Patent 7304029 Neuroprotective effect of growth hormone	Patent 7304029 was granted and assigned to Neuren Pharmaceuticals on December, 2007 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7304029	December 4, 2007
‌ US Patent 7041314 GPE analogs and peptidominetics	Patent 7041314 was granted and assigned to Neuren Pharmaceuticals on May, 2006 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7041314	May 9, 2006
‌ US Patent 9867823 Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders	Patent 9867823 was granted and assigned to Neuren Pharmaceuticals on January, 2018 by the United States Patent and Trademark Office.	‌ Neuren Pharmaceuticals	‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	9867823	January 16, 2018
‌ US Patent 11370755 Compositions of trofinetide	Patent 11370755 was granted and assigned to Neuren Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	‌ Neuren Pharmaceuticals	‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	11370755	June 28, 2022
‌ US Patent 8067425 Neuroprotective bicyclic compounds and methods for their use	Patent 8067425 was granted and assigned to Neuren Pharmaceuticals on November, 2011 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	8067425	November 29, 2011
‌ US Patent 9119851 Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals	Patent 9119851 was granted and assigned to Neuren Pharmaceuticals on September, 2015 by the United States Patent and Trademark Office.	‌ Neuren Pharmaceuticals	‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	9119851	September 1, 2015
‌ US Patent 7776876 Cyclic G-2Allylproline in treatment of Parkinson's disease	Patent 7776876 was granted and assigned to Neuren Pharmaceuticals on August, 2010 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7776876	August 17, 2010
‌ US Patent 7282342 Methods for detecting weakly immunogenic analytes	Patent 7282342 was granted and assigned to Neuren Pharmaceuticals on October, 2007 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7282342	October 16, 2007
‌ US Patent 8791117 Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals	Patent 8791117 was granted and assigned to Neuren Pharmaceuticals on July, 2014 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	8791117	July 29, 2014
‌ US Patent 7192931 Treatment of demyelinating diseases	Patent 7192931 was granted and assigned to Neuren Pharmaceuticals on March, 2007 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7192931	March 20, 2007
‌ US Patent 7112570 GPE analogs	Patent 7112570 was granted and assigned to Neuren Pharmaceuticals on September, 2006 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7112570	September 26, 2006
‌ US Patent 7767786 Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration	Patent 7767786 was granted and assigned to Neuren Pharmaceuticals on August, 2010 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	7767786	August 3, 2010
‌ US Patent 10548892 Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders	Patent 10548892 was granted and assigned to Neuren Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.	‌ Neuren Pharmaceuticals	‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	10548892	February 4, 2020
‌ US Patent 8138304 Neural regeneration peptides and formulations thereof	Patent 8138304 was granted and assigned to Neuren Pharmaceuticals on March, 2012 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	8138304	March 20, 2012
‌ US Patent 11197856 Bicyclic compounds and methods for their use in treating autism	Patent 11197856 was granted and assigned to Neuren Pharmaceuticals on December, 2021 by the United States Patent and Trademark Office.	‌ Neuren Pharmaceuticals	‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	11197856	December 14, 2021
‌ US Patent 6933282 Regulation of tyrosine hydroxylase by GPE	Patent 6933282 was granted and assigned to Neuren Pharmaceuticals on August, 2005 by the United States Patent and Trademark Office.		‌ Neuren Pharmaceuticals	United States Patent and Trademark Office	6933282	August 23, 2005

Results per page:

26 results

0 selected

26 results

0 selected